From: Immunosuppressive Glycodelin A is an independent marker for poor prognosis in endometrial cancer
Grade (%) | 1 | 147 (51.2) |
---|---|---|
(n = 287) | 2 | 93 (32.4) |
 | 3 | 47 (16.4) |
FIGO stage (%) | I | 219 (75.0) |
(n = 292) | II | 21 (7.2) |
 | III | 44 (15.1) |
 | IV | 8 (2.7) |
Histology (%) | Endometrioid | 212 (72.6) |
(n = 292) | Serous | 23 (7.9) |
 | Clear cell | 5 (1.7) |
 | Mucinous | 12 (4.1) |
 | Squamous cell | 1 (0.3) |
 | Mixed | 34 (11.6) |
 | Undifferentiated | 5 (1.7) |
Patient age ± sem [y] (range) |  | 65.1 ± 0.6 (35.6-88.1) |
Deaths (%) | Â | 160 (54.8) |
Survival ± sem [y] (95% CI) |  | 13.6 ± 0.5 (12.6-14.6) |
Follow up ± sem [y] (95% CI) |  | 13.8 ± 0.3 (13.1-14.5) |
Glycodelin (%) (n = 291) | Low | 79 (27.1) |
 | Intermediate | 152 (52.2) |
 | High | 60 (20.6) |
Glycodelin A (%) (n = 289) | Low | 82 (28.4) |
 | Intermediate | 181 (62.6) |
 | High | 26 (9.0) |
ER alpha (%) (n = 292) | Positive | 133 (45.5) |
ER beta (%) (n = 292) | Positive | 40 (13.7) |
PRA (%) (n = 292) | Positive | 121 (41.4) |
PRB (%) (n = 292) | Positive | 134 (45.9) |
Co-morbidities | Hypertension (%) | 116 (39.7) |
 | Diabetes (%) | 33 (11.3) |
 | Obesity (%) | 89 (30.5) |
Lymphangiosis (%) (n = 292) | Positive | 27 (9.2) |
 | Negative | 263 (90.1) |
 | Unknown | 2 (0.7) |
Hemangiosis (%) (n = 292) | Positive | 8 (2.7) |
 | Negative | 281 (96.2) |
 | Unknown | 3 (1.0) |
Radiotherapy (%) (n = 292) | Yes | 116 (39.7) |
 | No | 170 (58.2) |
 | Declined | 6 (2.1) |
Chemotherapy (%) (n = 292) | Yes | 7 (2.4) |
 | No | 283 (96.9) |
 | Declined | 2 (0.7) |